Alasdair Coles is a neurologist in Cambridge. He was closely involved in the development of alemtuzumab (“Lemtrada”) as a treatment of multiple sclerosis. Since then, he has set up trials of a novel remyelinating drug in multiple sclerosis and of immunotherapy in autoimmune psychosis.
![](https://cony.comtecmed.com/wp-content/uploads/2023/01/Alisdair-Coles_200.jpg)